Akoya Biosciences (AKYA) Stock Forecast & Price Target

$2.11 -0.01 (-0.47%)

(As of 11/22/2024 ET)

Akoya Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 8 Analyst Ratings

Sell
0

Hold
5

Buy
3

Based on 8 Wall Street analysts who have issued ratings for Akoya Biosciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 8 analysts, 5 have given a hold rating, and 3 have given a buy rating for AKYA.

Consensus Price Target

$5.43
157.28% Upside

According to the 8 analysts' twelve-month price targets for Akoya Biosciences, the average price target is $5.43. The highest price target for AKYA is $10.00, while the lowest price target for AKYA is $3.00. The average price target represents a forecasted upside of 157.28% from the current price of $2.11.

Get the Latest News and Ratings for AKYA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Akoya Biosciences and its competitors.

AKYA Analyst Ratings Over Time

Type	Current Forecast 11/26/23 to 11/25/24	1 Month Ago 10/27/23 to 10/26/24	3 Months Ago 8/28/23 to 8/27/24	1 Year Ago 11/26/22 to 11/26/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)
Hold	5 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$5.43	$6.56	$6.56	$8.60
Forecasted Upside	157.28% Upside	134.38% Upside	164.62% Upside	91.96% Upside
Consensus Rating	Hold	Moderate Buy	Moderate Buy	Buy

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

AKYA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AKYA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Akoya Biosciences Stock vs. The Competition

Type	Akoya Biosciences	Medical Companies	S&P 500
Consensus Rating Score	2.38	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	157.28% Upside	27,006.30% Upside	7.66% Upside
News Sentiment Rating	Negative News See Recent AKYA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/19/2024	Piper Sandler 2 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$4.00 ➝ $3.00	+42.86%
11/15/2024	Canaccord Genuity Group 1 of 5 stars		Lower Target	Buy ➝ Buy	$6.00 ➝ $3.50	+56.25%
11/15/2024	Craig Hallum 3 of 5 stars	B. Bonello Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$7.00 ➝ $5.00	+59.74%
8/6/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$4.00 ➝ $3.00	+50.00%
8/6/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Massaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/6/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral
Has Trump Finally Gone Too Far? (Ad) Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover
3/5/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$7.00 ➝ $7.50	+40.71%
12/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral
11/13/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$14.00 ➝ $9.00	+126.70%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 08:37 AM ET.

AKYA Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Akoya Biosciences is $5.43, with a high forecast of $10.00 and a low forecast of $3.00.
: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akoya Biosciences in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AKYA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKYA, but not buy additional shares or sell existing shares.
: According to analysts, Akoya Biosciences's stock has a predicted upside of 157.28% based on their 12-month stock forecasts.
: Over the previous 90 days, Akoya Biosciences's stock had 1 downgrade by analysts.
: Akoya Biosciences has been rated by research analysts at Canaccord Genuity Group, Craig Hallum, and Piper Sandler in the past 90 days.
: Analysts like Akoya Biosciences less than other "medical" companies. The consensus rating for Akoya Biosciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AKYA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

This page (NASDAQ:AKYA) was last updated on 11/25/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akoya Biosciences (AKYA) Stock Forecast & Price Target